Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI® (ribociclib ...

Tel Aviv University researchers say neutrophils can be late-stage breast cancer target and biomarker; Beilinson Hospital ...

For patients with metastatic HR+/HER2— breast cancer, there were various trials to have come out of ASCO 2025 that are worth keeping your eye on.

University of Cambridge study shows how LLM GPT-4 can generate novel combinations of drugs not typically used to treat cancer ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

Tumors are complex systems characterized by variations across genetic, transcriptomic, phenotypic, and microenvironmental ...

MacMillan has been named a Distinguished Scholar in the Princeton Branch of the Ludwig Institute for Cancer Research, which ...